Search
Selected Filter
Displaying 1–10 of 227 research results
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Development of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Projects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
The approach holds potential for restoring vision to people with little or no vision
-
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
More than 8,000 people have applied for genetic testing through the Foundation’s program
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
His latest Foundation grant is helping move the drug toward a clinical trial
-
Are You on the Clinical Trial Radar Screen?
Therapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Researchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
The company plans to enroll additional patients as young as four years old
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
